Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials (Q83961773)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 June 2006

Language	Label	Description	Also known as
English	Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials	scientific article published on 01 June 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765182 AND SRC:MED&resulttype=core&format=json

29 January 2020

0 references

Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765182 AND SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

based on heuristic

inferred from title

author name string

Rui Fa Han

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765182 AND SRC:MED&resulttype=core&format=json

29 January 2020

Jian Gang Pan

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765182 AND SRC:MED&resulttype=core&format=json

29 January 2020

publication date

1 June 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765182 AND SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765182 AND SRC:MED&resulttype=core&format=json

29 January 2020

67

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765182 AND SRC:MED&resulttype=core&format=json

29 January 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765182 AND SRC:MED&resulttype=core&format=json

29 January 2020

1216-1223

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765182 AND SRC:MED&resulttype=core&format=json

29 January 2020

Guidelines for reading case-control studies.

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

Treatment of high-risk superficial bladder cancer with maintenance bacille Calmette-Guérin therapy: preliminary results

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

The best management of superficial bladder tumours: comparing TUR alone versus TUR combined with intravesical chemotherapy modalities?

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisati

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2005.12.014

7 January 2021

Identifiers

10.1016/J.UROLOGY.2005.12.014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765182 AND SRC:MED&resulttype=core&format=json

29 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765182 AND SRC:MED&resulttype=core&format=json

29 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83961773&oldid=1812251515"